Biotechnology & Life Sciences Global On demand · 24-48h

Global Antibodies for Research Market Strategic Research Report

Global Antibodies for Research Market Strategic Research Rep…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Antibodies for Research Market
$1.66B2025
5.1%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Monoclonal, Polyclonal

By Application: Oncology, Neurobiology, Immunology, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Merck, Johnson and Johnson Services, Eli Lilly and Company, Bio-Rad Laboratories, Inc, Cell Signalling Technology, PerkinEImer, Rockland Immunochemicals, Novartis, BD, Abcam, Kamiya Biomedical, AMSBIO, Thermo Fisher Scientific, GeneTex, MCE, Shanghai Yanmai Biotechnology, Shanghai LONG ISLAND Antibody Diagnostica, SUNSHINE GUOJIAN PHARMACEUTICAL, Shanghai Junshi Biosciences

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 132 pages
Market size 2025
$1.66B
Billion USD
Forecast CAGR
5.1%
2025-2032
Forecast 2032
$2.4B
Projected
Regionen
5
Asia Pacific · Latin America · MEA · Europe · North America

Übersicht

Scope of the Report

The global Antibodies for Research market size is predicted to grow from US$ 1,655 million in 2025 to US$ 2,326 million in 2032; it is expected to grow at a CAGR of 5.1% from 2026 to 2032.

Research antibodies are divided into monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies, also called mAbs, are laboratory-made antibodies that bind to specific targets in the body, such as antigens on the surface of cancer cells. There are several types of monoclonal antibodies, and each mAb is designed to bind a single antigen. They can be used alone or in combination with other drugs to deliver drugs, toxins or radioactive substances directly to cancer cells.

Polyclonal antibody, also known as "polyclonal antibody" (Polyclonal Antibody), is an antibody mixture containing multiple types of antibodies. The "poly" in its name refers to the mixture of antibodies produced by different types of plasma cells.

Rising R&D activities in neurological, oncology, and stem cell research, increasing prevalence of cancer and infectious diseases, growing demand for antibodies, and increasing regulation across the biopharmaceutical industry are the key factors driving the research-based antibodies market revenue.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Antibodies for Research market?

What factors are driving Antibodies for Research market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Antibodies for Research market opportunities vary by end market size?

How does Antibodies for Research break out by Type, by Application?

This report presents a comprehensive overview of the global Antibodies for Research market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Monoclonal
  • Polyclonal

Segment by Application

  • Oncology
  • Neurobiology
  • Immunology
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Antibodies for Research market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Oncology, Neurobiology, Immunology evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Antibodies for Research Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5.1%
Regional growth momentum
Market share by segment
Key metrics
Base value
$1.66B
2025
Forecast
$2.4B
2032
CAGR
5.1%
2025–2032
Regionen
5
global
Key companies
MerckJohnson and Johnson ServicesEli Lilly and CompanyBio-Rad Laboratories, IncCell Signalling TechnologyPerkinEImerRockland ImmunochemicalsNovartis
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
MonoclonalPolyclonal
By Application
OncologyNeurobiologyImmunologyOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Monoclonal
  • 3.1.3 Polyclonal
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Oncology
  • 4.1.3 Neurobiology
  • 4.1.4 Immunology
  • 4.1.5 Others
  • 4.1.6 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Merck
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Johnson and Johnson Services
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Eli Lilly and Company
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Bio-Rad Laboratories, Inc
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Cell Signalling Technology
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 PerkinEImer
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Rockland Immunochemicals
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Novartis
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 BD
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Abcam
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Kamiya Biomedical
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 AMSBIO
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Thermo Fisher Scientific
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 GeneTex
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 MCE
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 Shanghai Yanmai Biotechnology
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Shanghai LONG ISLAND Antibody Diagnostica
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 SUNSHINE GUOJIAN PHARMACEUTICAL
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 Shanghai Junshi Biosciences
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Antibodies for Research market?
The global Antibodies for Research market is estimated at US$ 1.66 billion in 2025 (base year) and is projected to reach US$ 2.33 billion by 2032.
What is the forecast CAGR for the Antibodies for Research market?
The market is expected to grow at a CAGR of 5.1% from 2026 to 2032, expanding from US$ 1.66 billion in 2025 to US$ 2.33 billion in 2032, roughly 1.4 times its base-year value.
What is Antibodies for Research?
Research antibodies are divided into monoclonal antibodies and polyclonal antibodies. Monoclonal antibodies, also called mAbs, are laboratory-made antibodies that bind to specific targets in the body, such as antigens on the surface of cancer cells. There are several types of monoclonal antibodies, and each mAb is designed to bind a single antigen.
How is the Antibodies for Research market segmented by type?
By type, the market is segmented into Monoclonal and Polyclonal.
What are the key applications of Antibodies for Research?
Key applications covered include Oncology, Neurobiology, Immunology and Others.
Which companies are profiled in the Antibodies for Research market report?
Key players profiled include Merck, Johnson and Johnson Services, Eli Lilly and Company, Bio-Rad Laboratories, Cell Signalling Technology, PerkinEImer, Rockland Immunochemicals and Novartis, among 19 companies covered in total.
What geographies does the Antibodies for Research market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Antibodies for Research?
Rising R&D activities in neurological, oncology, and stem cell research, increasing prevalence of cancer and infectious diseases, growing demand for antibodies, and increasing regulation across the biopharmaceutical industry are the key factors driving the research-based antibodies market revenue.
Who should buy the Antibodies for Research market report?
The report is intended for manufacturers and solution providers, distributors and end users in Oncology, Neurobiology and Immunology, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Antibodies for Research market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3.500,00 $
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.